Drug Trial Radar · NCT06325566
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 3, 2024
Primary completion
Jul 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- Mesoblast, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.
Conditions
- Degenerative Disc Disease
Interventions
Rexlemestrocel-L + HA mixtureDrug
Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.
SalineDrug
Saline solution injection adjacent to the index disc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Daily Average Low Back Pain at 12 Months Post-treatment Based on Visual Analog Scale (VAS) ScoreTime frame: Baseline and Month 12
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Month 24
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Axsendo Clinical Research/Summa Pain Care
Phoenix, Arizona
Pain Institute of Southern Arizona
Tucson, Arizona
TriWest Research Associates
Chula Vista, California
Boomerang Health Care
Concord, California
Apex Research Group
Fair Oaks, California
Memorial Orthopaedic Surgical Group
Long Beach, California
Newport Therapeutics
Newport Beach, California
University of California-Davis Spine Center
Sacramento, California
Innovative Pain Treatment Solutions
San Diego, California
University of California-San Francisco
San Francisco, California
Source Healthcare
Santa Monica, California
Colorado Spine Partners/The Denver Spine and Pain Institute
Greenwood, Colorado
Cantor Spine Center at the Paley Orthopedic & Spine Institute
Fort Lauderdale, Florida
New Life Medical Research Center
Hialeah, Florida
Bold City Clinical Research
Jacksonville, Florida
Interventional Pain Institute
The Villages, Florida
Conquest Research LLC
Winter Park, Florida
Emory Healthcare
Dunwoody, Georgia
Vista Clinical Research
Newnan, Georgia
Hawaii Pain & Spine
Kailua, Hawaii
University of Kansas Medical Center
Kansas City, Kansas
Iqra Research
Edgewood, Kentucky
Paradigm Health System
Slidell, Louisiana
The Kahan Center
Annapolis, Maryland
Elevate Clinical Research
Rockville, Maryland
Oasis Clinical Research
Las Vegas, Nevada
Reno Tahoe Pain Associates
Reno, Nevada
University of Rochester
Rochester, New York
Eximia EquiHealth Research LLC/Emerge Ortho
Durham, North Carolina
AdventHealth Hendersonville
Hendersonville, North Carolina
Meta Medical Research Institute, LLC
Dayton, Ohio
Clinical Investigations, LLC
Edmond, Oklahoma
OSS Health
York, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Clinical Trials of South Carolina
Charleston, South Carolina
Institute of Precision Pain Medicine
Corpus Christi, Texas
Paradigm Research Center/Houston Scoliosis and Spine Institute
Houston, Texas
Axsendo Clinical Research/Texas Institute of Pain and Spine
Pearland, Texas
VA iSpine Physicians
Richmond, Virginia
West Virginia University
Martinsburg, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.